- Home
- WEX vs RYTM Comparison
WEX vs RYTM Comparison
Compare WEX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEX
- RYTM
- Stock Information
- Founded
- WEX 1983
- RYTM 2008
- Country
- WEX United States
- RYTM United States
- Employees
- WEX N/A
- RYTM N/A
- Industry
- WEX Business Services
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- WEX Consumer Discretionary
- RYTM Health Care
- Exchange
- WEX Nasdaq
- RYTM Nasdaq
- Market Cap
- WEX 5.8B
- RYTM 6.4B
- IPO Year
- WEX 2005
- RYTM 2017
- Fundamental
- Price
- WEX $158.34
- RYTM $97.86
- Analyst Decision
- WEX Hold
- RYTM Strong Buy
- Analyst Count
- WEX 13
- RYTM 13
- Target Price
- WEX $180.91
- RYTM $109.77
- AVG Volume (30 Days)
- WEX 331.5K
- RYTM 627.7K
- Earning Date
- WEX 10-23-2025
- RYTM 11-04-2025
- Dividend Yield
- WEX N/A
- RYTM N/A
- EPS Growth
- WEX 37.64
- RYTM N/A
- EPS
- WEX 7.93
- RYTM N/A
- Revenue
- WEX $2,598,200,000.00
- RYTM $156,287,000.00
- Revenue This Year
- WEX $1.02
- RYTM $46.10
- Revenue Next Year
- WEX $5.27
- RYTM $60.39
- P/E Ratio
- WEX $20.00
- RYTM N/A
- Revenue Growth
- WEX N/A
- RYTM 53.55
- 52 Week Low
- WEX $110.45
- RYTM $45.91
- 52 Week High
- WEX $217.47
- RYTM $106.52
- Technical
- Relative Strength Index (RSI)
- WEX 40.27
- RYTM 49.11
- Support Level
- WEX $156.09
- RYTM $95.88
- Resistance Level
- WEX $161.95
- RYTM $102.79
- Average True Range (ATR)
- WEX 4.15
- RYTM 3.20
- MACD
- WEX -0.58
- RYTM -0.25
- Stochastic Oscillator
- WEX 12.08
- RYTM 32.99
About WEX WEX Inc. common stock
WEX Inc is a provider of corporate payment solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. The company's prime end market is the United States of America.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.